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We examined whether prediagnostic JC virus (JCV) anti-
bodies and viremia are predictors of progressive multifocal
leukoencephalopathy (PML) in 83 PML cases and 240 human
immunodeficiency virus (HIV) disease-matched controls.
JCV viremia was not predictive of PML, but some patients
showed higher anti-JCV immunoglobulin G (IgG) responses
6 months prior to diagnosis.
Progressive multifocal leukoencephalopathy (PML) is a de-
myelinating disease of the central nervous system caused by
lytic infection of oligodendrocytes with JC polyomavirus
(JCV). PML occurs in immunosuppressed individuals with
AIDS or hematological malignancies, transplant recipients, and
patients treated with immunomodulatory medications for
autoimmune diseases [1–3].
Clinically useful predictors for PML are lacking. We therefore
performed nested case-control studies within the Multicenter-
AIDS and the Swiss-HIV (human immunodeficiency virus)
cohort studies (MACS and SHCS) to examine whether JCV-
specific virological and serological markers are predictors of
PML.
METHODS
The study was approved by the institutional review board (IRB)
at each participating center and each MACS location.
Study Populations
Two nested case-control studies were performed using archived
samples from the MACS, a prospective study of HIV/AIDS in
homosexual men in the United States begun in 1984, and the
SHCS, a prospective study of HIV-1 infected Swiss adults ini-
tiated in 1988. Demographic and clinical data, plasma, serum,
and peripheral blood mononuclear cells (PBMC) were col-
lected every 6 months for 2.5 years prior to PML diagnosis, and
additionally for 1 year after diagnosis in the SHCS. Thirty PML
patients fromMACS were diagnosed between 1985 and 1996 by
brain histology in 16 (53%), radiographic and clinical signs in 9
(30%), and clinical diagnosis in 5 (17%) patients. Cases were
matched with 81 HIV-seropositive participants, who did not
develop PML. In the SHCS, 53 patients were diagnosed with
PML between 1995 and 2006 by brain histology in 7 (13%),
detection of JCV by polymerase chain reaction (PCR) in ce-
rebral spinal fluid in 18 (34%) and radiographic and clinical
signs in 28 (53%) patients. Cases were matched with 149 HIV-
seropositive participants. Criteria for matching are described in
supplementary materials.
JCV PCR Assays
Plasma and PBMC samples were tested by quantitative
PCR (QPCR) for JCV DNA (as described elsewhere [4] and
supplementary materials).
JCV Serology Assays
A virus-like particle-based enzyme-linked immunosorbent assay
(ELISA) was used to detect antibody to JCV capsids (as de-
scribed elsewhere [5] and supplementary materials).
Statistical Analysis
Conditional logistic regression, with adjustment for age and
CD41 T-cell counts at diagnosis, was used to investigate the
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temporal relationship between PML and levels of log-transformed
immunoglobulin (Ig) G, IgA, and IgM optical density values,
serostatus, and plasma JCV DNA copy number.
RESULTS
Study Population
Within each study, demographic characteristics of cases and
controls were similar (Table 1). MACS participants were men,
while one-fifth of SHCS patients were women. Intravenous drug
use was more common in SHCS (39.6%) than in MACS
(12.6%). One case in MACS received combined antiretroviral
therapy (cART), but 30 (57%) cases in SHCS were treated with
cART. Within SHCS, cases and controls were well matched at
entry and at PML diagnosis, while median CD41 T-cell counts
ofMACS cases at the time of PML diagnosis were lower than that
of controls (139 cells/uL vs 171 cells/uL, P 5 .01).
Serological Studies
Among the 83 PML cases and 230 controls, JCV IgG seropre-
valence was 58% and 49%, respectively, 1–1.5 years before
diagnosis, and did not differ substantially during other 6-month
intervals before PML diagnosis. IgA seroprevalence among cases
and controls 1–1.5 years before diagnosis was 16% and 11%,
while IgM seroprevalence was 2.2% and 3.4%, respectively. After
PML diagnosis, IgG seroprevalence increased to 96% in the
6 months following diagnosis, while IgA and IgM seroprevalence
increased to 50% and 12.5%, respectively (analysis restricted to
SHCS). Among subjects with 2 or more IgG measurements,
8 cases (15.1%) and 15 controls (9.4%) seroconverted. Fluctu-
ating serostatus was observed in 8.6% of controls and 11.3% of
cases. Treatment with cART had no effect on JCV-specific capsid
IgG and IgM levels, whereas a trend for IgA seropositivity was
seen (adjusted odds ratio [OR], 3.1, 95% confidence interval
[CI], .99–9.74, P 5 .052).
The distribution of IgG, IgA, and IgM seroreactivity to JCV
capsids during 6-month time intervals prior to PML diagnosis is
shown in Figure 1. Six months prior to diagnosis, median (in-
terquartile range) IgG levels for cases and controls were 0.23
(0.13, 0.40) and 0.18 (0.08, 0.35), respectively, and the median
difference between matched case-control sets was 0.06 (20.11,
0.23). Controlling for CD41 T-cell count and age, a 1 log10
Table 1. Characteristics of Study Populations
MACS SHCS
Variable Cases (n 5 30) Controls (n 5 81) Cases (n 5 53) Controls (n 5 149)
Gender, N (%)
Male 30 (100%) 81 (100%) 33 (77%) 118 (79%)
Female 0 (0%) 0 (0%) 10 (23%) 31 (21%)
Age, median (IQR) 39 (36, 44) 40 (36,51) 39 (34, 43) 38 (35, 43)
Race/ethnicity, N (%)
White 29 (97%) 79 (98%) 44 (83%) 129 (87%)
Black 0 (0%) 2 (2%) 1 (2%) 8 (5%)
Other/unknown 1 (3%) 0 (0%) 8 (15%) 12 (8%)
Ever IV drug use, N (%)
No 26 (87%) 71 (88%) 32 (60%) 70 (47%)
Yes 4 (13%) 10 (12%) 21 (40%) 79 (53%)
Ever smoking, N (%)
No 7 (23%) 31 (38%) NA NA
Yes 23 (77%) 50 (62%) NA NA
Years on study, median (IQR) 6.6 (4.0, 8.4) 7.1 (4.9, 9.3) 4.6 (0.25, 7.8) 6.4 (1.8, 9.7)
PML diagnostic criteria
Histological/virological 16 (53%) NA 25 (47%) NA
Clinical/radiographic 14 (47%) NA 28 (53%) NA
Calendar Yr Dx, median (IQR) 1991 (1989, 1994) NA 1999 (1997, 2002) NA
Entry CD4, median (IQR) 549 (363, 631) 483 (375, 636) 274 (90, 440) 216 (105, 430)
CD4 at Dx, median (IQR) 139 (87, 206) 171 (90, 280) 139 (44, 257) 120 (57, 218)
cART in 2 yrs before PML
No 29 (97%) 81 (100%) 23 (43%) NA
Yes 1 (3%) 0 (0%) 30 (57%) NA
Abbreviations: cART, combined antiretroviral therapy; IQR, interquartile range; MACS, Multicenter AIDS Cohort Study; NA, not available; SHCS, Swiss HIV Cohort
Study.
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increase in JCV capsid-specific IgG level in cases compared
with controls was associated with a 75% increase in the odds
of developing PML (hazard ratio [HR], 1.75, 95% CI, 1.19–
2.58, P 5 .0046). The association of IgG with risk of PML was
observed in the combined analysis of 83 PML cases and in the
53 SHCS cases, but only a non-significant trend was seen in
the 30 MACS cases. IgA and IgM levels were not associated
with risk of PML. Comparable results were obtained when the
analysis was restricted to the 36 PML cases confirmed histo-
logically and/or virologically and their 114 controls. Antibodies
to JCV capsid increased post PML diagnosis. The median
IgG level was higher in SHCS cases compared with controls
during the first 6-month interval (0.54 vs 0.24, P , .0001) and
the 6–12 month interval (0.68 vs 0.23, P ,.001) after diagnosis
(Figure 2).
Virological Studies
JCV DNA was detected by QPCR in plasma from 14 (17%) of
83 cases and 28 (12%) of 230 controls. The median detectable
level of JCV DNA was 168 copy numbers per mL of plasma
(interquartile range, 108–364). Detecting JCV viremia prior to
diagnosis was not associated with a risk of developing PML.
Of 42 subjects with viremia at 1 or more visits, 12 (29%) were
seronegative at all visits. Six (26%) of 23 PML cases had de-
tectable JCV DNA in PBMC samples during the 2 years prior
to the diagnosis of PML, and the corresponding number for
controls was 15 (17%) of 90 patients (P 5 .36).
DISCUSSION
We combined data from 2 nested case-control analyses to
examine risk factors for development of PML in HIV-infected
patients. Our study population of 83 PML cases is large for
this rare disease. A striking finding was that JCV viremia did
not have any diagnostic use for the risk of developing PML in
the 2 years before diagnosis. The frequency of JC viremia in
our study (13.4%) was lower than that reported for HIV-
positive patients in some studies, which ranged between 20%
and 40% [6–8].
The prevalence of IgG to JCV capsids and the level of an-
tibody did not differ between cases and controls during any
6-month time window between 2.5 and 0.5 years before PML
diagnosis. However, in the 6 months immediately preceding
diagnosis of PML, the level of JCV capsid antibody was ele-
vated in cases compared with controls, as reported elsewhere
[9]. The association was largely due to the contribution of
53 cases from the SHCS. We cannot rule out that undefined
technical and clinical factors, such as sample size, storage
conditions, or the use of cART, contribute to this difference.
The temporal proximity to the diagnosis of PML suggests that
this association may reflect underlying disease. In a previous
study in MACS, higher titers of JCV IgG were associated with
JCV viruria but not to a diagnosis of PML [10] In total, 25%
of HIV-positive individuals who developed PML were sero-
negative on 1 or more visits during the 2 years prior to di-
agnosis. It is not clear if seronegative patients were truly
negative or if they had levels of antibodies too low to be scored
as positive by our assay. In total, 29% of patients with JCV
viremia were seronegative, supporting the notion that the
Figure 1. Distribution of IgG, IgA, and IgM absorbance values of sera
from PML cases and HIV disease matched controls in the MACS and
SHCS at time intervals before the diagnosis of PML. The summary
statistics of each distribution are displayed in a box plot. The length of the
box corresponds to the interquartile range with the upper boundary of the
box representing the 75th percentile and the lower boundary the 25th
percentile. The horizontal clear line in the box represents the median
value. The 10th and 90th percentiles are shown by the small bar at the
end of the line extending downward or upward, respectively, from the
box. Each outlier value is shown individually by a solid line. The number of
outliers that are not displayed in the graph space is indicated at the top of
each graph. The number of samples contributing to each distribution is
indicated at the bottom of the figure.
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assay was not very sensitive in the setting of advanced HIV
infection. We speculate, therefore, that an increase in JCV IgG
activity may reflect recent exposure to JCV antigen, which, in
a severely immunosuppressed patient, might also indicate an
increased risk of developing PML, while a stable IgG titer does
not preclude subsequent development of PML.
One limitation of our study is the use of samples that had
been kept frozen for long periods of time. It is possible that
degradation of viral DNA precluded efficient amplification of
JCV sequences. The JCV seroprevalence was lower in MACS
(42%) than SHCS (67%) and lower than that reported in other
populations [11, 12]. Nevertheless, the absence of viremia before
PML diagnosis is consistent with models of pathogenesis, which
hypothesize that PML is caused by reactivation in the brain
either from virus resident in the brain or from virus in cells that
traffic to the brain.
Interest in prediagnostic markers of PML has been triggered
by the recent development of PML in multiple sclerosis and
Crohn’s disease patients treated with natalizumab, and psoriasis
patients treated with efalizumab [3]. The selective impairment in
T-cell activation and trafficking caused by these drugs differs
from immunosuppression seen in AIDS. Therefore, while it is
not clear if the findings of our study are readily applicable to
patients treated with these drugs, the study does suggest that
monitoring these patients for JCV viremia is unlikely to predict
who will develop PML.
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